Synergy Pharmaceuticals (SGYP) Stock Soars after Positive Results for Plecanatide
July 30, 2015 at 09:32 AM EDT
Shares of Synergy Pharmaceuticals Inc. (SGYP) were trading up +1.74 or +21.19 percent to $9.95 per share in Thursday's premarket after the company announced positive results in the second Phase 3 trial of its gastrointestinal drug plecanatide in patients suffering from Chronic Idiopathic Constipation or CIC. Synergy Pharmaceutical stock closed at $8.21 per share, down ... READ MORE Read the rest of Synergy Pharmaceuticals (SGYP) Stock Soars after Positive Results for Plecanatide at InvestorGuide.com .
